tion, graft loss and mortality after transplantation to patients with IgA nephropathy has been proposed [6 ], Background. Based on graft survival rates it has been claimed that patients with IgA nephropathy have a and the view seems to have gained acceptance [7 ] . A mechanism of action for such an effect has also been reduced risk of rejection after kidney transplantation. We wanted to evaluate this hypothesis.
Introduction
ing. The proportion of patients with cadaveric donors who received grafts without foreign HLA DR antigens was 19%.
IgA nephropathy was first described in 1968 [1 ] and is In the period, the waiting time has ranged from 18 to 24 the most common form of chronic glomerulonephritis months, including any time before initiation of dialysis. (CGN ) [2] [3] [4] [5] . Only a minority of patients ever develop Premptive transplantation was performed in 23% of all end-stage renal disease but IgA nephropathy has been patients. reported to be the original disease in about 10% of During the entire period, immunosuppression was based kidney transplant patients [4] . A reduced risk of rejec-on cyclosporin A and prednisolone. For the first 2 years, patients took part in a randomized study evaluating the effect of adding azathioprine. After that, triple drug therapy delayed onset of graft function, when cyclosporin was with-between IgA nephropathy patients and their matched held. Antirejection therapy consisted of methylprednisolone controls, P=0.51. Seven patients with IgA nephroin bolus doses on 4 consecutive days, followed by a second pathy died, one within the first year with pancreatitis, course, ATG or OKT 3 in resistant cases.
perforations of the colon, and a never-functioning Patients living in the Gö teborg area were followed at our graft, the others later due to infections (2), malignant out-patient clinic. For the other patients, reports were sent disease (2) or coronary heart disease (2) . Nine control at least once a year from the local renal units. In addition, patients died, four within the first year of pneumonitis patients were seen in the unit at regular follow-up visits 6 (3 ) or pancreatitis (1), five later of coronary heart months and 1, 3, 5 and 10 years after transplantation. The disease (4) In total, 20 of 70 grafts transplanted to patients with frequencies and the Mann-Whitney U test to test non-certified IgA nephropathy were lost during follow-up, normally distributed values. P values above 0.05 were considered non-significant. Table 1 shows demographic data for IgA nephropathy patients, the matched controls, and the entire cohort of transplant patients in the time period. IgA nephropathy patients were significantly younger at the time of transplantation than the rest of the patients in the entire cohort, n=874, P<0.0001. There was also a higher proportion of men (P=0.003) and of transplantations from living donors (P<0.0001). Thirtyseven of 70 IgA nephropathy patients had living donors; 23 were parents, 11 siblings, 2 spouses, and one was an uncle.
Results
For patients with cadaveric donors, there was no difference from the total cohort in the degree of HLA DR mismatching. The proportion of transplantations degree of DR mismatching, which turned out to be followed for a minimum of 3 years. The number of patients/controls similar.
actually followed for 5 years is 47/50. There are no significant differences between the groups.
There was no significant difference in patient survival and 20 of the controls' grafts. In the IgA nephropathy policies for obtaining kidney biopsies in the USA. If a renal biopsy is not a regular procedure, a young patient group, 7 graft losses occurred early (within 6 months), caused by never-functioning graft (1 ), acute biopsy-in a good general physical condition is probably more likely to be subjected than a weaker candidate. verified rejection (5 ), or chronic vascular rejection ( 1). Recurrence of IgA nephropathy was the major cause Furthermore, it is possible that the diagnosis has not been confirmed by biopsy in each case, as in our series, of late graft loss (5) . The total number of graft loss caused by rejection was similar in IgA nephropathy but was sometimes based on inconclusive clinical indications such as a history of episodes of haematuria patients and controls, as shown in Table 2 . The Table  also shows that the rejection rates during the first year triggered by infections. In another published study, the diagnosis was set on clinical grounds in the majority and the mean number of days when any antirejection treatment were given was not different.
of patients [11] . Another possible uncertainty is the way survival was calculated: not more than half of the patients would Discussion actually have been followed for 3 years when the results of transplantations performed in [1985] [1986] [1987] [1988] [1989] [1990] were calculated in early 1991. Our study confirms previous reports of good overall If there is a true difference in the experience from results of transplantation to patients with IgA nephroour centre and the accumulated data of the UCLA pathy [6, 7, 10] . This is true especially for patient surRegistry, this might be connected with different policies vival, which was superior to that in the contemporary for HLA matching. In such a case, HLA matching cohort (data not shown), probably related to the fact would be more favourable in IgA nephropathy patients that IgA patients were significantly younger. In conthan in patients with other diagnoses. We find this trast, there was no significant difference from the hypothesis somewhat far-fetched. controls matched for age. The UCLA Registry also A recent French study of kidney transplantation to reported reduced mortality in patients with IgA patients with IgA nephropathy reports excellent graft nephropathy [6 ] . Their control group, however, was survival, 75.2% at 5 years, but with no control group not matched and, like our main group, may have for comparison [7] . Another study including about the differed from the study patients in several respects same numbers as in our study reports no advantage of other than underlying renal disorder.
IgA nephropathy with respect to graft survival [12 ] , Graft survival rates were almost identical with those yet with data presented in a condensed form which in the closely matched controls. Even when split precludes detailed comparison with the UCLA data or according to type of donor, graft survival curves for our data. IgA nephropathy patients and controls remained very Survival of kidney transplants is most often presumed similar. In contrast to our finding, superior survival of to depend on acute or chronic rejection. We have in first grafts from cadaveric donors was reported in IgA fact investigated and analysed reasons for graft loss nephropathy patients compared with the rest of the and found that the incidence of graft loss due to patients in the UCLA Registry [6 ] . This difference was rejection was not reduced in IgA nephropathy patients. also seen when only patients aged 20-50 years were Finally, the incidence and severity of rejection episodes compared. However, the average age in each group was not reduced. No corresponding data have been was not published and may have differed considerably published previously. within this range.
In summary, there was no indication of a reduced The possibility that IgA nephropathy patients risk of rejection in IgA nephropathy patients. reported to the UCLA Registry represented a positive selection, for instance were more often from excellent centres, was not, in our opinion, ruled out. In particular, the prevalence of IgA nephropathy was lower than References expected, about 3% to be compared with our 8.0%. Only 128 of more than 200 centres had reported any patient at all with this diagnosis. This probably reflects
